放化疗对局部晚期非小细胞肺癌患者外周血VEGF的影响  

Effect of Radiotherapy and Chemotherapy on VEGF of Peripheral Blood in Patients with Locally Advanced Non-small Cell Lung Cancer

作　　者：年亮 胡海峰[1] 

机构地区：[1]延安大学附属医院,716000

出　　处：《实用癌症杂志》2016年第12期1936-1939,共4页The Practical Journal of Cancer

摘　　要：目的 探讨Ⅲ期非小细胞肺癌患者采用同步放化疗治疗的临床疗效及对患者外周血VEGF、生存期的影响。方法 按照随机抛硬币法将74例Ⅲ期非小细胞肺癌患者分组为对照组（序贯放化疗）与观察组（同步放化疗）,分别为37例。随访6~60个月,平均为（42.6±9.4）个月。统计两组患者临床疗效、生存时间及治疗期间所产生的不良反应,采用酶联免疫法检测两组患者治疗前、后外周血VEGF水平。结果 观察组临床治疗有效率为67.57%,明显高于对照组（48.65%）,P〈0.05;观察组平均生存时间为（19.9±4.1）个月,明显长于对照组[（12.5±3.4）个月],P〈0.05。两组主要不良反应为消化道反应和骨髓抑制剂放射性食管炎,但两组不良反应发生率比较,P〉0.05。治疗后,观察组外周血VEGF水平较治疗前显著下降,对照组较治疗前显著升高,两组患者改善程度与治疗前比较,P〈0.05;然而观察组优于对照组,P〈0.05。结论 应用同步放化疗治疗Ⅲ期非小细胞肺癌疗效显著且安全;此外,同步放化疗可降低患者因化疗所诱导的外周血VEGF表达,从而降低患者外周血VEGF水平,抑制肿瘤增殖及转移。Objective To study the clinical efficacy of concurrent chemoradiotherapy for stage llI non-small cell lung cancer（NSCLC） and its effect on VEGF of peripheral blood and survival. Methods 74 cases of lung cancer patients with stage Ⅲ NSCLC were randomly divided into the control group （sequential chemotherapy） and the observation group （chemoradiotherapy）, each with 37 cases. Followed up for 6 -60 months, an average of（42.6±9.4） months. Clinical efficacy, survival and adverse reactions of the 2 groups were recorded, peripheral blood VEGF before and after treatment were detected by enzyme-linked immunosorbent assay. Results Clinical effective rate of the observation group was 67.57% which was significantly higher than the control group,48.65 %, P 〈 0.05 ;the average survival time of the observation group was （ 19.9±4.1 ） months, which was signifi- cantly longer than the control group（ 12.5±3. g） months, P 〈 0.05. Major adverse reactions were gastrointestinal reactions and bone marrow inhibitors esophagitis, but adverse reaction rate between the 2 groups had no significant difference, P 〉 0.05. After treatment, VEGF in peripheral blood of the observation group before treatment decreased significantly, which was significantly higher than the control group, compared to before treatment, there had no significant difference, P 〈 0.05 ;however, the observation group was superior to the control group,P 〈 0.05. Conclusion Concurrent chemotherapy and radiotherapy for stage Ⅲ non-small cell lung cancer is effective and safe;in addition, concurrent chemoradiotherapy can reduce chemotherapy-induced VEGF expression in peripheral blood, thereby reducing peripheral VEGF level, inhibiting tumor proliferation and metastasis.

关 键 词：Ⅲ期非小细胞肺癌 同步放化疗 生存期 序贯放化疗 外周血VEGF 

分 类 号：R734.2[医药卫生—肿瘤]